Skip to main content
S&P 5007,656.98+0.86%DOW52,573.29+0.98%NASDAQ26,333.03+0.96%BTC$77,267.00+0.58%ETH$2,510.86+2.27%GOLD$4,390.00-0.39%OIL$99.99-2.43%
Smart Investors Daily
Actinium Pharmaceuticals, Inc. logo

AMEX · ATNM

Actinium Pharmaceuticals, Inc.

Healthcare · Biotechnology

$1.40

Up+$0.09 (+6.87%)

Updated Sep 13, 2026, 12:50 AM

SID Score

5.3/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
45.55M
P/E ratio
-1.32
Dividend yield
0.00%
52-week range
$0.74 – $1.74
Volume
242.66K
Avg. volume
205.89K

Price performance

ATNM price history

1M range · 19 trading sessions · Daily adjusted prices

ATNM closed at $1.40 after 19 trading sessions, up 33.33% for the selected period.

Last close
$1.40
Period change
+33.33%
Period low
$1.00
Period high
$1.40
Daily close
View OHLC price history
ATNM OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 11, 2026$1.31$1.42$1.285$1.40242.66K
Sep 10, 2026$1.25$1.34$1.2301$1.31226.76K
Sep 9, 2026$1.24$1.305$1.22$1.23366.57K
Sep 8, 2026$1.06$1.25$1.06$1.23574.18K
Sep 4, 2026$1.05$1.055$1.02$1.0354.23K
Sep 3, 2026$1.02$1.0599$1.01$1.0578.76K
Sep 2, 2026$1.00$1.04$1.00$1.0077.57K
Sep 1, 2026$1.01$1.0224$0.9955$0.995530.07K
Aug 31, 2026$1.03$1.03$1.01$1.0234.78K
Aug 28, 2026$1.00$1.0276$0.97$1.01112.02K
Aug 27, 2026$1.01$1.05$1.00$1.0092.87K
Aug 26, 2026$1.08$1.08$1.01$1.01145.24K
Aug 25, 2026$1.07$1.10$1.0501$1.08159K
Aug 24, 2026$1.10$1.10$1.04$1.0564.45K
Aug 21, 2026$1.13$1.14$1.10$1.10144.01K
Aug 20, 2026$1.13$1.14$1.07$1.12121.42K
Aug 19, 2026$1.09$1.15$1.05$1.13183.41K
Aug 18, 2026$1.05$1.115$1.03$1.08211.2K
Aug 17, 2026$1.11$1.13$1.05$1.05344.94K

Latest ATNM news

The latest Smart Investors Daily articles mentioning ATNM.

Stock researchCompany · Overview

ATNM research

Overview

Company profile and research snapshot.

Company profile

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$11.07
Implied upside
—
Analysts
11
ATNM recent ratings
DateFirmRatingTarget
Mar 31, 2026Stephens & Co.Overweight—
Jun 24, 2025HC Wainwright & Co.Buy—
May 12, 2025HC Wainwright & Co.Buy—
Apr 28, 2025HC Wainwright & Co.Buy—
Apr 1, 2025HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 4, 2026

Actinium Pharmaceuticals, Inc. to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced that Sandesh Seth, Chairman and Chief Executive Officer, will present at the H.C. Wainwright 28th Annual Global Investment Conference, being held September 14-16, 2026, in New York, NY. Company management will also be available for one-on-one meetings with investors.

Yahoo · Aug 14, 2026

Actinium Pharmaceuticals Announces Actimab-A Intellectual Property and Manufacturing Advances and Provides NYSE American Listing Update

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced advances across its Actimab-A program, including recently acquired patents adding to a broad suite of IP, and expansion of the Company's manufacturing capacity, as the program approaches clinical milestones from the fourth quarter of 2026 and into 2027. The Company also provided an update on the status of its NYSE American listing.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By